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Background: The ubiquitous second messenger Ca2+ has been demonstrated to play an important role in cancer
progression. Store-operated Ca2+ entry (SOCE) is the main Ca2+ entry pathway regulating intracellular Ca2+
concentration in a variety of cancer types. The present study aimed to explore the specific mechanisms of SOCE in
the processes of glioma migration and invasion.
Methods: The expression of Orai1, a key component of SOCE, was examined in glioma samples and glioma cell lines
by immunohistochemistry and western blot analysis. Both pharmacological intervention and RNA interference were
employed to investigate the role of SOCE in glioma cell migration and invasion in vitro. The intracellular Ca2+ was
certified through Fluo-4/AM based Ca2+ measurement. The effect of SOCE on cell viability, migration, and invasion was
explored by methyl thiazolyl tetrazolium (MTT) assay, wound healing assay, transwell invasion assay. Western blot
analysis and immunofluorescence assay were used to observe the changes of downstream related protein and cell
morpholog.
Results: Orai1 expression was elevated in glioma tissues and several glioma cell lines compared with
non-neoplastic brain tissues. Either inhibition of SOCE by a pharmacological inhibitor or Orai1 downregulation
suppressed glioma cell migration and invasion. However, re-expression of Orai1 could rescue glioma cell motility.
Furthermore, phosphorylation of proline-rich tyrosine kinase 2 (Pyk2) participated in the mechanisms by which
SOCE regulated focal adhesion turnover and epithelial-to-mesenchymal (−like) transition in glioma cells, both of
which are considered to be critical for tumor progression.
Conclusions: The SOCE-Pyk2 pathway is essential for glioma migration and invasion. The study indicates the
potential value of Orai1 as a molecular target for anti-invasion therapy.
Keywords: Store-operated Ca2+ entry, Glioma, Focal adhesion turnover, Epithelial-to-mesenchymal (−like)
transition, Proline-rich tyrosine kinase 2Background
Gliomas are the most common primary tumors in the
central nervous system (CNS), and glioblastoma multi-
forme (GBM) has the poorest prognosis among glioma
types. Even with the current optimal therapeutic strategies,
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unless otherwise stated.months after diagnosis [1]. Clinical and histologic evidence
has shown that glioma cells always disperse along thin and
elongated anatomic structures such as white matter fibers,
capillaries, and unmyelinated axons [2]. For this reason,
glioma cells cannot be completely resected by surgical
treatment, which leads to recurrence and poor prognosis.
Therefore, new treatment approaches that inhibit glioma
cell invasion and migration represent as urgent medical
need. The identification of new molecular regulators re-
lated to tumor progression may provide potential targets
for future therapeutic strategies.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plays an important role in many fundamental physio-
logical processes, including cell excitability, exocytosis,
motility, apoptosis, and transcription [3]. Recent research
indicates that Ca2+ also contributes to several malignant
behaviors in tumors, such as proliferation, invasion, mi-
gration, and metastasis [4,5]. There are a variety of Ca2+
entry pathways in cells. Store-operated Ca2+ entry (SOCE),
which is initiated by the depletion of intracellular Ca2+
stores, is an important pathway in nonexcitable cells [6].
SOCE is mediated by store-operated Ca2+ channels
(SOCs), including stromal interacting molecule-1 (STIM1)
and Orai1. The vast majority of STIM1 is located in the
endoplasmic reticulum (ER) membrane, and Orai1 is lo-
cated in the plasmalemma. When external stimuli cause
Ca2+ release from the ER, store depletion is sensed by
STIM1. STIM1 then moves near to the cell membrane
and interacts directly with Orai1. As the essential pore-
forming component of SOCs, Orai1 opens and mediates
entry of many Ca2+ ions. Recently, SOCE has been impli-
cated in tumor cell progression. Inhibition of SOCE was
shown to suppress human breast cancer cell migration
both in vitro and in vivo [7]. The specific mechanisms in-
clude SOCE-mediated induction of a higher rate of focal
adhesion turnover and accelerated migration velocity of
cancer cells, whereas a reduction in SOCE resulted in lar-
ger focal adhesions, slowing their turnover and conse-
quently increasing adherence. Similar studies were
performed in cervical cancer and hepatocarcinoma, and the
results also support the above conclusion [8,9].
One study of SOCE in glioblastoma found suppression
of SOCE inhibits human glioblastoma cell proliferation
and induces G0/G1 phase arrest [10]. Another research
group found that downregulation of STIM1 and Orai1
in primary human glioblastoma cell lines results in a signifi-
cant decrease in tumor cell invasion in vitro [11]. However,
the study did not investigate the morphological changes of
tumor cells and the specific downstream mechanisms. In
the current study, we verified the expression of Orai1 in dif-
ferent grades of glioma tissues and several glioma cell lines.
More importantly, we found that SOCE regulates focal ad-
hesion turnover and epithelial-to-mesenchymal (−like)
transition (EMT-like) in glioma cells by modulating
proline-rich tyrosine kinase 2 (Pyk2) phosphorylation.
Methods
Cell culture
The human glioma cell lines U251, SNB19, U87, and
LN229 and the rat glioma cell line C6 were purchased
from the Chinese Academy of Sciences Cell Bank
(Beijing, China). All cell lines were cultured in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Solarbio, Beijing,
China) in an atmosphere of 5% CO2 at 37°C.Sample collection
Glioma samples were obtained from 61 patients by surgi-
cal resection in the Department of Neurosurgery, Tianjin
Medical University General Hospital between July 2008
and December 2012. Eight non-neoplastic normal brain
tissues were obtained from patients with temporal lobe
epilepsy. For immunohistochemical analysis, samples were
fixed in 4% paraformaldehyde and embedded in paraffin.
Samples for western blot analysis were stored in liquid ni-
trogen. The pathological diagnosis and grading for each
glioma were assessed by neuropathologists according to
the 2007 World Health Organization (WHO) Classifica-
tion of Nervous System Tumors [12]. All samples were
obtained at primary resection, including 13 low-grade gli-
oma samples (WHO II, n = 13) and 48 high-grade glioma
samples (WHO III, n = 12; WHO IV, n = 36), and none of
the patients had undergone radiation therapy or chemo-
therapy before surgery. All patients and their relatives pro-
vided written informed consent. Sample collection was
performed in accordance with the ethical standards of the
Helsinki Declaration and approved by the ethical commit-
ted of Tianjin Medical University General Hospital.
Antibodies and reagents
The following antibodies were used: rabbit monoclonal
anti-Orai1 and mouse monoclonal anti-vinculin (Abcam,
Cambridge, UK); rabbit polyclonal anti-Pyk2 and mouse
monoclonal anti-E-cadherin (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); mouse monoclonal anti-
phosphorylated Pyk2 (p-Pyk2) (Tyr402; R&D Systems,
Minneapolis, MN, USA); rabbit monoclonal anti-N-
cadherin and rabbit monoclonal anti-vimentin (Cell Sig-
naling Technology, Danvers, MA, USA); Alexa Fluor
594-conjugated goat anti-mouse IgG (H + L) antibody
(Invitrogen, Carlsbad, CA, USA); Alexa Fluor 488-
conjugated goat anti-rabbit IgG (H + L) antibody (Cell
Signaling Technology).
Important reagents were as follows: thapsigargin,
SKF96365, puromycin, and G418 from Sigma-Aldrich (St.
Louis, MO, USA); and Fluo-4/AM and Pluronic-127
from Invitrogen. Boyden chambers were purchased
from Millipore (Billerica, MA, USA) and Matrigel was
purchased from BD Biosciences (San Jose, CA, USA).
Confocal Petri dishes were obtained from NEST Bio-
technology (Wuxi, JS, China).
Immunohistochemistry
Paraffin-embedded samples were sectioned using a
microtome into 5-μm-thick sections for immunohisto-
chemical staining. Nonspecific proteins were blocked
using goat serum, and then the slides were incubated
separately in the primary antibody solution (rabbit anti-
Orai1, 1:200 dilution) overnight at 4°C. Antibodies
bound to Orai1 were stained with DAB substrate after
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secondary antibody. Images were acquired using an
Olympus VANOX microscopy at magnifications of × 100
and × 200. The results were evaluated by two independ-
ent pathologists. The intensity of positively stained cells
was scored from 0–3 according to the extent of staining
from 0%–100%: 0 for 0%, 1 for 1–33%, 2 for 34–66%,
and 3 for 67–100%.
Western blot analysis
Western blot analysis was carried out as previously de-
scribed [13]. Samples were broken into small pieces, and
cells were cultured to 90% confluence before harvesting.
After total proteins were extracted, 30 μg of each sample
was analyzed by sodium dodecyl sulfate (SDS)-polyacryl-
amide gel electrophoresis (PAGE) on 10% acrylamide
gels and processed using the antibodies listed above.
Western blot analysis was performed with an enhanced
chemiluminescence (ECL) kit (Millipore). Each experi-
ment was repeated three times independently. Quanti-
tative evaluation of protein expression was performed
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). The average gray values of target
proteins (normalized to that for glyceraldehyde 3-
phosphate dehydrogenase GAPDH expression) are pre-
sented in the figures.
Cell viability assay
The methyl thiazolyl tetrazolium (MTT) assay was used
to evaluate cell viability. Cells were plated in a 96-well
culture plate (5 × 103 cells/well) in regular growth
medium for 24 h. Then cells were treated with 20 μM
SKF96365 and maintained in culture for 72 h. At time
points of 0, 24, 48, and 72 h, assays were initiated by
adding 20 μl MTT substrate to each well and incubating
cells for another 4 h to allow metabolism of the MTT.
Finally, the medium was removed and 200 μl dimethyl
sulfoxide (DMSO) was added to each well. The absorb-
ance of each well was read at 490 nm using an auto-
mated microplate reader (Bio-Rad, Hercules, CA,
Canada). All experiments were performed in triplicate.
Wound healing assay
Glioma cells were evenly plated in a 6-well culture plate
and allowed to reach 70% confluence. Then wounds
were made by scratching the cell layer using a 200-μl
sterile pipette tip. In the presence of serum, cells should
migrate and fill the wound within approximately 48 h.
Images were acquired using an Olympus IX71 inverted
microscope at magnification of × 100. The images shown
are representative of three independent experiments.
The numbers of migrated cells between the two edges of
the gap in five random fields were counted for further
quantitative analysis.Transwell invasion assay
Boyden chambers with a pore size of 8 μm were coated
with Matrigel in DMEM (1:3 ratio) in advance. Then
Boyden chambers were coated with 20 μl of the com-
pound evenly and incubated at 37°C for 30 min. Glioma
cells (5 × 104 in 200 μl DMEM without FBS) were plated
on the top side of the Matrigel-coated Boyden chambers.
The lower compartments were filled with DMEM supple-
mented with 10% FBS. After incubation for 36 h, the non-
invasive cells on the upper surface of the membranes were
gently removed using cotton swabs and the invasive cells
on the lower surface were fixed with 4% paraformalde-
hyde, stained with crystal violet, and counted (five random
fields per well). All experiments were repeated three times
independently.
Immunofluorescence assay
Cells were plated in confocal Petri dishes coated with
poly-L-lysine (1 mg/ml) and incubated overnight for ad-
herence. Then, cells were fixed at room temperature
with 4% paraformaldehyde for 10 min and permeabilized
with 0.1% Triton X-100. Cells were incubated with pri-
mary antibodies overnight at 4°C and stained by Texas
Red or fluorescein isothiocyanate (FITC)-labeled second-
ary antibody. Cell nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) staining solution. All
images were taken using an Olympus FV-1000 confocal
microscope.
RNA interference and rescue experiment
Small hairpin RNA (shRNA) directed against Orai1 was
generated using the GV112 vector (U6-MCS-CMV-puro-
mycin) (GeneChem, Shanghai, China). The sequence used
was 5′-CGTGCACAATCTCAACTCG-3′ [7]. Cells trans-
fected with shOrai1 were selected using puromycin (5 μg/
ml). The cDNA construct for re-expression of Orai1 was
obtained by site-directed mutation of the targeting se-
quences without changing the amino acid sequence. The
mutant was subcloned into a GV141 vector (CMV-MCS-
3FLAG-SV40-Neomycin) (GeneChem, Shanghai, China).
Cell stably transfected with shOrai1 were transfected with
the Orai1 rescue construct and selected again using G418
(1 μg/ml). The shRNA plasmid for Pyk2 knockdown was
purchased from Santa Cruz Biotechnology and was a pool
of three target-specific 19–25-nt small interfering RNAs
(siRNAs) designed to knock down gene expression. The
control shRNA plasmid was also provided. Lipofectamine
2000 reagent (Invitrogen) was used for transfection of the
Orai1 construct and shPyk2. The whole process was per-
formed according to the manufacturer’s instructions.
Intracellular Ca2+ measurement
To measure intracellular Ca2+ in glioma cells, we used
Fluo-4/AM, a cell-permeable fluorescent Ca2+ indicator,
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Ca2+ measurement contained 140 mM NaCl, 2 mM
CaCl2, 5 mM KCl, 0.45 mM KH2PO4 ,0.4 mM Na2HPO4,
1.2 mM MgSO4, 1.2 mM MgCl2, 4.2 mM NaHCO3,
10 mM glucose, and 5 mM HEPES (pH 7.4). Fluo-4/AM
was mixed with an equal volume of 20% Pluronic-127 and
diluted in standard solution to a final concentration of
5 μM. Glioma cells plated in confocal Petri dishes were
washed with standard solution and incubated with Fluo-4/
AM for 30 min at 37°C protected from light. Fluo-4–
loaded cells were then washed three times and allowed to
stabilize for 10 min in standard solution. Cells were then
stabilized in Ca2+-free solution (which contained 0 Ca2+)
for 10 min, and again with standard solution for another
10 min. The ER Ca2+ ATPase inhibitor thapsigargin
(5 μM) was added 3 min after the start of superfusion with
Ca2+-free solution and was continuously present there-
after. Thapsigargin was used to induce store depletion,
which would lead to the activation of SOCE. SOCE activ-
ity was checked by measuring the increase in intracellular
Ca2+ upon return to standard solution. The dynamic
change in fluorescence intensity was monitored at 5-s in-
tervals using an Olympus FV-1000 confocal microscope.
Data curves were drawn to reflect the dynamic change in
intracellular Ca2+.
Statistical analysis
All quantified data represent an average of at least tripli-
cate experiments unless otherwise indicated, and stand-
ard deviations were calculated. All statistical analyses
were performed using SPSS 19.0 (SPSS, Inc., Chicago,
IL, USA) and GraphPad Prism 5.0 (GraphPad Software,
La Jolla, CA, USA). Comparisons among all groups were
performed using one-way analysis of variance (ANOVA)
or unpaired Student’s t-tests. P < 0.05 was considered to
be statistically significant.
Results
Orai1 expression in glioma samples and glioma cell lines
As one important Ca2+ membrane channel protein, Orai1
is the key component that mediates SOCE. To study the
role of SOCE in glioma migration and invasion, we first
assessed the expression levels and subcellular localization
of Orai1 in 61 glioma samples and 8 non-neoplastic brain
tissues by immunohistochemistry. Representative immu-
nohistochemical staining patterns for Orai1 are shown in
Figure 1A. Positive staining for Orai1 was mainly localized
in the cytoplasm and plasmalemma at varying levels. The
data showed that non-neoplastic brain tissues expressed
low levels of Orai1, but Orai1 expression was positively
correlated with the WHO grading of gliomas. Compared
with non-neoplastic brain tissues, low-grade gliomas
(WHO II, n = 13) displayed slightly elevated Orai1 protein
expression, whereas high-grade gliomas (WHO III, n = 12;WHO IV, n = 36) showed a significantly elevated Orai1 ex-
pression compared with non-neoplastic brain tissues and
low-grade samples (Figure 1B).
Next, Orai1 protein expression was detected in non-
neoplastic brain tissues, human glioma samples (WHO
II and IV), and five typical glioma cell lines by western
blot analysis. The results are shown in Figure 1C. Orai1
was commonly overexpressed at higher levels in glioma
samples (WHO II and IV) and in all glioma cell lines
compared with non-neoplastic brain tissues.SKF96365 inhibited migration and invasion of glioma cells
The overexpression of Orai1 in glioma tissues and cell
lines leads us to believe that SOCE may be involved in
the migration and invasion of glioma cells. U251 and
SNB19 glioma cells were used in the following experi-
ments. First, we investigated the influence of SKF96365
on the malignant behavior in glioma cells. SKF96365, an
imidazole compound, was introduced as an pharmaco-
logical inhibitor of SOCE in cell lines in the concentra-
tion range of 20–30 μM [15]. SKF96365 has been widely
used in various recent studies related to SOCE [7,9].
We performed MTT assays to evaluate the toxicity of
SKF96365 at the tested concentration (20 μM). Follow-
ing the manufacturer’s instructions, SKF96365 was dis-
solved in sterile deionized water, which has no effect on
glioma cells. We found that the viability of U251/SNB19
glioma cells was not impaired (P > 0.05) by treatment
with SKF96365 (20 μM) for 72 h compared with the
solvent control (Figure 2A).
Wound healing assays were performed to observe the
influence of SKF96365 on glioma cell migration. For both
U251 and SNB19 cells, SKF96365 significantly inhibited
the migration of tumor cells by 66%–80% (Figure 2B). The
invasive ability of glioma cells was assessed via migration
assays using Matrigel-coated Boyden chambers. The
numbers of migrating cells in the SKF96365-treated
groups were decreased by 79%–85% compared with the
control groups (Figure 2C). These results suggest that
SOCE may play an important role in controlling the
motility of glioma cells.SKF96365 inhibited focal adhesion turnover, EMT-like,
and the activity of Pyk2 in glioma cells
Several previous studies have shown that SOCE is in-
volved in tumor cell migration and invasion via modula-
tion of focal adhesion turnover. We therefore sought to
determine whether SOCE plays the same role in glioma
cells. Therefore, we investigated the expression of several
EMT-related markers and the activity of Pyk2, an intra-
cellular calcium-dependent tyrosine kinase that is acti-
vated through phosphorylation and considered essential
for both focal adhesion disassembly and EMT.
Figure 1 Expression of Orai1 in glioma samples and glioma cell lines. (A) Representative patterns of Orai1 expression in non-neoplastic brain
tissues and glioma samples of different grades by immunohistochemistry. NB, non-neoplastic brain tissues. Magnification, ×200. (B) Intensity
scores for STIM1 and Orai1 expression by immunohistochemistry. The data are shown as mean ± standard deviation (SD). **P < 0.01 (WHO II vs.
NB, WHO III–IV vs. NB, and WHO III–IV vs. WHO II). (C) Western blot analysis of Orai1 expression in non-neoplastic brain tissues, glioma samples (WHO II
and IV), and five typical glioma cell lines. The gray values represent the means of three independent experiments (normalized to GAPDH expression).
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labeling for vinculin, a major component of focal adhe-
sions. U251/SNB19 cells plated on poly-L-lysine (1 mg/
ml)-coated confocal Petri dishes were treated with medium
with or without SKF96365 (20 μM) for 3 h, fixed in 4%
paraformaldehyde, and then stained with anti-vinculin anti-
body. Control tumor cells showed a normal morphology
characterized by irregular shape and stretched pseudopodia.
Vinculin immunofluorescent labeling showed a punctate or
threadlike pattern of small focal adhesions in control cells
(Figure 3A). However, treatment with SKF96365 led to cell
rounding and induced large peripheral adhesions while de-
creasing the number of adhesions in the center area of the
cell (Figure 3A). Large peripheral focal adhesions were ob-
served in 80%–90% of cells treated with SKF96365, but in
only 6%–8% of control cells (Figure 3B).
Then, the protein expression of three important EMT-
related markers was analyzed by western blotting. The re-
sults showed that E-cadherin (an epithelial marker) was
expressed at extremely low levels in both glioma cell lines,
whereas it was significantly upregulated after treatment
with SKF96365 for 3 h (Figure 3C), suggesting a shift to-
wards epithelial phenotype. Consistently, the expression of
two mesenchymal markers, N-cadherin and vimentin, was
decreased upon treatment with SKF96365 (Figure 3C). Our
results clearly demonstrate that treatment with SKF96365
promotes epithelial cell characteristics and suppresses mes-
enchymal features in glioma cells. Next, we detected the ex-
pression and phosphorylation of Pyk2 at the Tyr402 site.
The results indicated that the total Pyk2 levels were nearly
unchanged, whereas the levels of p-Pyk2 were significantly
decreased in both cell lines after treatment with SKF96365
(Figure 3D).Orai1 controlled glioma cell motility and phosphorylation
of Pyk2
Based on the results presented above, we hypothesized
that modulating SOCE via targeting of Orai1 could also
impact the motility of glioma cells. Orai1 was stably
knocked down in U251/SNB19 cells by transfection with
Orai1 shRNA. Western blot analysis and Ca2+ measure-
ments were employed to confirm the efficiency of RNA
interference. Transfection of cells with shOrai1 signifi-
cantly downregulated the expression of Orai1 compared
with transfection with shControl (Figure 4A). However, the
reduction could be rescued by re-expression of Orai1 res-
cue construct (Figure 4A). Through Fluo-4–based intracel-
lular Ca2+ measurement, we found that downregulation of
Orai1 did reduce the amplitude of Ca2+ influx in tumor
cells, but re-expression of the Orai1 construct could rescue
the loss of Ca2+ influx (Figure 4B). Therefore, we obtained
three groups of U251/SNB19 cells: the shControl group,
the shOrai1 group, and the Orai1 rescue group.
To test our hypothesis, we detected the protein levels
of total Pyk2 and p-Pyk2 in the three groups of U251/
SNB19 cells. Western blot analysis showed that p-Pyk2 was
significantly downregulated in shOrai1 cells, whereas total
Pyk2 expression was comparable between the shOrai1 and
shControl cells (Figure 4C). We also observed that Orai1
rescue was able to nearly counteract the decrease in p-Pyk2
caused by Orai1 downregulation (Figure 4C). The results
suggest that Orai1 is essential for the phosphorylation of
Pyk2. Meanwhile, when the total Pyk2 was knocked down
by a Pyk2-specific shRNA plasmid (shPyk2) in the Orai1
rescue group, p-Pyk2 was also reduced (Figure 4C). Then,
migration assays using Matrigel-coated Boyden chambers
indicated that the number of migrating cells was
Figure 2 SKF96365 inhibited migration and invasion of U251 and SNB19 glioma cells. (A) The effect of SKF96365 at the tested
concentration (20 μM) on U251 and SNB19 cell viability as measured by MTT assay. Absorbance was read at 490 nm with averages from triplicate
wells. (B and C) Wound healing assays and migration assays employing Matrigel-coated Boyden chambers were performed to investigate the
effect of SKF96365 on the migration and invasion of U251 and SNB19 cells. Data are presented as means ± SDs of nine different microscopic
visions from three independent experiments. **P < 0.01.
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with the shControl group (Figure 4D). Similarly, re-
expression of Orai1 could rescue the invasive ability of gli-
oma cells (Figure 4D). However, the invasion of glioma
cells in the Orai1 rescue group was suppressed again upon
p-Pyk2 downregulation (Figure 4D).
Orai1 regulated focal adhesion turnover and EMT-like via
phosphorylation of Pyk2
To investigate the effect of Orai1 expression on focal ad-
hesion turnover, U251/SNB19 cells transfected with
shControl, shOrai1, Orai1 rescue, or shPyk2 were sub-
jected to vinculin staining as described above. Similarly,
we found that Orai1 downregulation led to cell rounding
and induced large peripheral adhesions, although not as
effectively as the inhibitor (Figure 5A). Re-expression of
Orai1 rescued this change but Pyk2 downregulation in-
creased the size of focal adhesions again (Figure 5A).
Large focal adhesions were observed in 11%, 66%, 18%,and 52% of U251 cells and 13%, 50%, 18%, and 41% of
SNB19 cells in the shControl, shOrai1, Orai1 rescue,
and shPyk2 groups, respectively (Figure 5B).
We also postulated that Orai1 may influence the
expression of EMT markers via the Pyk2 pathway.
Western blot analysis showed that the expression of E-
cadherin in the shOrai1 group was significantly in-
creased, whereas the expression of N-cadherin and
vimentin was significantly decreased compared to that
in the shControl group (Figure 5C). We also observed
that all three markers were restored to nearly the ori-
ginal levels in the Orai1 rescue group (Figure 5C). How-
ever, changes occurred again in the shPyk2 group
(Figure 5C). These results suggest that Orai1 regulates
EMT-like in glioma cells via the Pyk2 pathway.
Discussion
In this study, we tested the hypothesis that the Ca2+
entry pathway SOCE is essential for glioma progression.
Figure 3 SKF96365 inhibited focal adhesion turnover, EMT-like, and Pyk2 phosphorylation in U251 and SNB19 glioma cells. (A and B)
Immunofluorescent staining for vinculin showed differences in focal adhesions between the control and SKF96365-treated glioma cells. Magnification,
×1000. The proportions of cells with large focal adhesions are presented as means ± SDs of nine different microscopic visions from three independent
experiments. **P < 0.01. (C) Western blot analysis of E-cadherin, N-cadherin, and vimentin in U251 and SNB19 cells treated with SKF96365. (D) Western
blot analysis of the total Pyk2 and p-Pyk2 in U251 and SNB19 cells after treatment with SKF96365. The gray values represent the means of three
independent experiments (normalized to GAPDH expression).
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reports that implicated a link between SOCE and a var-
iety of tumors. The study of Yang et al. for the first time
demonstrated the important role of SOCE in breast can-
cer progression [7]. They found that blocking SOCE im-
pairs focal adhesion turnover, which can be rescued by
the small GTPases Ras and Rac. Another study also
showed that SOCE plays an important role in cervical
cancer growth, migration, and angiogenesis [8]. How-
ever, the exact role of SOCE in glioma progression and
its underlying mechanism have remained unclear. In the
present study, we unraveled the role of SOCE in focal
adhesion turnover and EMT-like in glioma cells, which
involves modulation of Pyk2 phosphorylation. The major
findings of this study are: (1) blockage of SOCE by a
pharmacological inhibitor (SKF96365) or Orai1 down-
regulation can suppress glioma cell invasion and migra-
tion; (2) SKF96365 and Orai1 downregulation induce
large focal adhesions and inhibit EMT-like in glioma
cells; (3) SKF96365 and Orai1 downregulation reduce
the phosphorylation of Pyk2; (4) re-expression of Orai1
can rescue all of the changes described above resulting
from Orai1 downregulation; and (5) Pyk2 silencing in-
hibits cell invasion, induces large focal adhesions, and
inhibits EMT-like in glioma cells again compared with
the Orai1 rescue group.The results of immunohistochemistry and western blot
analyses indicated that the expression of Orai1, the key
component of SOCE, is significantly correlated with the
WHO grading of gliomas, with very low Orai1 expres-
sion in non-neoplastic brain tissues and very high Orai1
expression in glioblastoma samples and five glioma cell
lines. Therefore, Orai1 may serve as a novel therapeutic
target, and we selected Orai1 as the molecular target for
studying the role of SOCE in subsequent experiments.
Two different approaches were employed to verify the
role of SOCE in glioma cell migration and invasion.
U251 and SNB19 cells were treated with the Ca2+ influx
inhibitor SKF96365 and RNA interference, respectively.
In the inhibitor group, we found that SKF96365 at the
tested concentration (20 μM) did not impair cell viabil-
ity but significantly inhibited the motility of glioma
cells. Moreover, in the RNA interference group, we
established glioma cell lines stably transfected with
shControl, shOrai1, or Orai1 rescue. The results of Ca2+
measurements showed that Orai1 strongly controlled
Ca2+ influx. Migration assays using Matrigel-coated
Boyden chambers were performed to confirm the role
of Orai1 in glioma cell invasion. The results showed
that Orai1 promoted the invasive ability of glioma cells,
suggesting that SOCE is crucial for the migration and
invasion of glioma cells.
Figure 4 Orai1 controlled U251 and SNB19 cell invasion through regulation of Pyk2 activity. (A) The expression of Orai1 in U251 and
SNB19 cells transfected with shControl, shOrai1, or Orai1 rescue by western blot analysis. (B) Changes in Ca2+ influx in U251 and SNB19 cells
transfected with shControl, shOrai1, or Orai1 rescue according to Fluo-4 Ca2+ measurements. Each trace was obtained by averaging data from
25–45 single cells. TG, thapsigargin. (C) Western blot analysis of the total Pyk2 and p-Pyk2 in U251 and SNB19 cells transfected with shControl,
shOrai1, Orai1 rescue, or shPyk2. (D) Invasive ability of U251 and SNB19 cells transfected with shControl, shOrai1, Orai1 rescue, or shPyk2 as
examined by Matrigel-coated Boyden chamber assays. Data are presented as means ± SDs of nine different microscopic visions from three
independent experiments. **P < 0.01.
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http://www.jeccr.com/content/33/1/98Several signaling molecules are believed to be regu-
lated by Ca2+. Pyk2, also as known as cell-adhesion kin-
ase β (CAKβ) or calcium-activation dependent tyrosine
kinase (CADTK), is a new member of the focal adhesion
kinase (FAK) family, with a highly homologous sequence
to FAK [16]. Phosphorylation activation of Pyk2 via its
Tyr402 residue usually depends on increasing intracellu-
lar Ca2+. An early study indicated that Pyk2 is located in
focal adhesions and regulates multiple signaling events
crucial for focal adhesion turnover [8]. Pyk2 is alsoknown to be able to control cell motility through the regu-
lation of genes associated with EMT [17,18]. Lipinski et al.
demonstrated that Pyk2 plays a crucial role in the migra-
tory behavior of glioblastomas [16,19]. Our study found
that p-Pyk2 was expressed in different grades of glioma
tissues, and increased with increasing malignancy of tu-
mours (Additional file 1: Figure S1). However, despite this
evidences for the role of Pyk2 in gliomas, the precise
mechanism by which pyk2 promotes glioma dispersion re-
mains elusive. Therefore, we tried to investigate the
Figure 5 Orai1 regulated focal adhesion turnover and EMT-like by modulating Pyk2 phosphorylation. (A) Representative Orai1 (green)
and vinculin (red) staining in U251 and SNB19 cells transfected with shControl, shOrai1, Orai1 rescue, or shPyk2. Magnification, ×1000. (B)
Proportions of cells with large focal adhesions are presented as means ± SDs of nine different microscopic visions from three independent
experiments. **P < 0.01. (C) Western blot analysis of E-cadherin, N-cadherin, and vimentin expression in U251 and SNB19 cells transfected with
shControl, shOrai1, Orai1 rescue, or shPyk2.
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http://www.jeccr.com/content/33/1/98possibility that Pyk2 is an immediate effector of SOCE and
that it controls the downstream mechanisms. The results
from our study indicated that SOCE did regulate the phos-
phorylation of Pyk2. When SOCE was blocked by
SKF96365, the expression of p-Pyk2 was decreased. Simi-
larly, the phosphorylation of Pyk2 was under the control
of Orai1.
Assembly and disassembly of focal adhesions are re-
quired for cell migration [20]. The continuous formation
and disassembly of focal adhesions is termed focal adhe-
sion turnover. The speed of focal adhesion turnover
largely determines the speed of cell migration [7]. To in-
vestigate the mechanism by which SOCE controls gli-
oma cell motility via the regulation of focal adhesion
turnover, vinculin staining was employed to visualize
focal adhesions. We found that SKF96365 induced large
focal adhesions due to the resulting defects in focal ad-
hesion turnover. Although not as effective as SKF96365,
downregulation of Orai1 was able to create the same ef-
fect, whereas re-expression of Orai1 attenuated it. Then,to further understand the mechanism by which SOCE
regulates focal adhesion turnover, we investigated the
participation of Pyk2. When Orai1 rescue cells were
transfected with a plasmid containing shRNA targeting
Pyk2, large focal adhesions appeared again. A series of
experiments demonstrated that SOCE regulates focal ad-
hesion turnover via phosphorylation of Pyk2.
EMT, which is characterized by the loss of epithelial
markers and the acquisition of mesenchymal markers,
may enhance cancer cell migration and invasion in order
to facilitate the development of metastasis [21-23].
There have been many thorough studies regarding EMT
in cancers outside the CNS. However, the role of EMT
in malignant gliomas still remains indistinct and contro-
versial, likely because the brain lacks critical tissue com-
ponents (i.e., epithelium and mesenchyme) [24]. The
majority of GBMs do not show intrinsic E-cadherin ex-
pression [25], and only a small subfraction of highly E-
cadherin–positive GBMs was observed [26]. Properly,
EMT-like has been described to represent the EMT
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http://www.jeccr.com/content/33/1/98process in glioma [27]. In our attempt to test the func-
tion of SOCE in EMT-like, we examined the expression
changes of three important EMT-related markers by
western blot analysis. We found that control U251 and
SNB19 cells almost did not express E-cadherin, whereas
its expression was increased in SOCE-inhibited cells. N-
cadherin and vimentin expression showed trends oppos-
ite to that of E-cadherin, suggesting that SOCE is crucial
for EMT-like in glioma cells. Our results also demon-
strate that Pyk2 participated in the regulation of EMT-
like by SOCE.
Conclusions
Our findings suggest that SOCE enhances glioma cell mi-
gration and invasion via regulation of focal adhesion turn-
over and induction of EMT-like. In addition, Pyk2 is an
important immediate effector of SOCE that mediates
downstream mechanisms. Thus, SOCE is likely to become
a novel therapeutic approach in treating malignant glioma.
Orai1, the key component of SOCE, may become a mo-
lecular target for glioma diagnosis and treatment.
Additional file
Additional file 1: Figure S1. Expression of p-Pyk2 in human gliomas.
(A) Immunohistochemistry of paraffin sections revealed that the expression
levels of p-Pyk2 in non-neoplastic brain tissues and glioma tissues were
quite different. NB, non-neoplastic brain tissues. Magnification, ×200. (B)
Expression of p-Pyk2 in U251 and SNB19 glioma cells was detected by
immunofluorescence. Magnification, ×400. (C) Western blot analysis of
p-Pyk2 expression in non-neoplastic brain tissues, glioma samples (WHO II
and IV), and two glioma cell lines.
Abbreviation
SOCE: Store-operated Ca2+ entry; MTT: Methyl thiazolyl tetrazolium;
CNS: Central nervous system; GBM: Glioblastoma multiforme; SOCs:
Store-operated Ca2+ channels; STIM1: Stromal interacting molecule-1;
ER: Endoplasmic reticulum; EMT-like: Epithelial-to-mesenchymal (−like)
transition; DMEM: Dulbecco’s Modified Eagle’s Medium; FBS: Fetal bovine
serum; WHO: World Health Organization; p-Pyk2: phosphorylated Pyk2;
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; DMSO: Dimethyl
sulfoxide; SDS: Sodium dodecyl sulfate; PAGE: Polyacrylamide gel
electrophoresis; ECL: Enhanced chemiluminescence; CAKβ: Cell-adhesion
kinase β; CADTK: Calcium-activation dependent tyrosine kinase; FAK: Focal
adhesion kinase.
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